First personalised cancer vaccine cuts risk of disease returning in major trial

A new personalised cancer vaccine given alongside a widely used immunotherapy drug has cut the risk of patients dying or their skin cancer returning by 42% in a major clinical trial.
The researchers involved say the results could mark a turning point in cancer treatment, bringing personalised medicine a step closer.
The trial also found that the new drug combination reduced the risk of melanoma, a type of skin cancer, spreading by 38% over two years compared to immunotherapy alone.
Opens BBC News in a new tab